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Mutant huntingtin is expressed in
neuronal and non-neuronal cells to cause
Huntington’s disease. Huang et al.
demonstrate that mutant huntingtin in
oligodendrocytes affects myelin gene
expression and causes age-dependent
neurological symptoms in transgenic
mice.
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Growing evidence indicates that non-neuronal
mutant huntingtin toxicity plays an important role in
Huntington’s disease (HD); however, whether and
how mutant huntingtin affects oligodendrocytes,
which are vitally important for neural function and
axonal integrity, remains unclear. We first verified
the presence of mutant huntingtin in oligodendro-
cytes in HD140Q knockin mice. We then established
transgenic mice (PLP-150Q) that selectively express
mutant huntingtin in oligodendrocytes. PLP-150Q
mice show progressive neurological symptoms and
early death, as well as age-dependent demyelination
and reduced expression of myelin genes that are
downstream of myelin regulatory factor (MYRF or
MRF), a transcriptional regulator that specifically ac-
tivates and maintains the expression of myelin genes
in mature oligodendrocytes. Consistently, mutant
huntingtin binds abnormally to MYRF and affects
its transcription activity. Our findings suggest that
dysfunction of mature oligodendrocytes is involved
in HD pathogenesis and may also make a good ther-
apeutic target.
INTRODUCTION
Huntington’s disease (HD) is caused by polyglutamine expan-
sion in the N-terminal region of huntingtin (Htt), a large protein
that consists of 3,141 amino acids. Despite the ubiquitous
expression of mutant Htt in the brain and peripheral tissues,
the major pathological feature of HD is selective neurodegener-
ation (Vonsattel and DiFiglia, 1998; Munoz-Sanjuan and Bates,
2011). Similarly, selective neurodegeneration is also seen
in many other neurodegenerative diseases, among them Alz-
heimer’s and Parkinson’s diseases, which suggests that multiple
factors may contribute to selective neurodegeneration. Given1212 Neuron 85, 1212–1226, March 18, 2015 ª2015 Elsevier Inc.the known genetic mutation in HD and its well-characterized
neuropathology, HD makes an ideal model for investigating
how selective neuropathology can be caused by a disease pro-
tein that is widely expressed.
Most previous studies have focused on the effect ofmutant Htt
on neuronal cells and revealed that N-terminal fragments of
mutant Htt are pathogenic and cause cell-autonomous or non-
cell-autonomous disease processes in a variety of animalmodels
(Heng et al., 2008; Li and Li, 2012; Lee et al., 2013). In the brain,
more than90%of cells are non-neuronal cells that provide essen-
tial support to the survival and function of neuronal cells. These
non-neuronal cells consist mainly of three types of glial cells:
astrocytes, microglial cells, and oligodendrocytes. Glial dys-
function has been well documented to contribute to a variety
of neurodegenerative diseases. For example, oligodendrocyte
dysfunction plays an important role in amyotrophic lateral scle-
rosis (ALS) (Fu¨nfschilling et al., 2012; Philips et al., 2013; Kang
et al., 2013). In HD patient brains, glial degeneration and pathol-
ogy have also been documented (Rosas et al., 2003; Fennema-
Notestine et al., 2004; Bartzokis et al., 2007; Di Paola et al.,
2012; 2014). For example, myelin damage and breakdown were
found in presymptomaticHDpatients (Bartzokis et al., 2007; Phil-
lips et al., 2014), and white matter defects in HD patients were
found to associate with motor and cognitive deficits (Bohanna
et al., 2011). Recent studies show that mutant Htt is expressed
in glial cells and affects the function of astrocytes (Shin et al.,
2005; Bradford et al., 2009; Tong et al., 2014) andmicroglial cells
(Crotti et al., 2014). For example, as in neuronal cells, mutant Htt
in astrocytes can affectmultiple targets, includingGLT-1 to affect
glutamate uptake (Shin et al., 2005; Bradford et al., 2009) and K
channel function (Tong et al., 2014) to increase striatal neuronal
excitability and vulnerability. Moreover, deficient myelination is
seen in HD mouse models (Wade et al., 2008; Xiang et al.,
2011). Nonetheless, because deficient myelination can be
caused by multiple factors including neuronal and non-neuronal
toxicity, whether and howmutantHtt affects the function of oligo-
dendrocytes remain to be investigated.
The importance of investigating mutant Htt’s effects in oligo-
dendrocytes is supported by the critical role of oligodendrocytes
in maintaining axonal function and early pathological changes in
Figure 1. Expression of Mutant Htt in Oligo-
dendrocytes in HD 140Q KI Mouse Brain
(A) PLP-GFP mice were crossed with HD 140Q KI
mice, and the brain striatum of the crossed mice
(PLP-GFP/KI) at 1 year of age was examined via
immunofluorescent staining with anti-Htt (red).
Arrows: GFP-positive oligodendrocytes (green)
also express mutant Htt (red), though neuronal
cells show more abundant Htt staining. The scale
bar represents 10 mm.
(B) In the brain cortex sections that reveal pro-
cesses of GFP-positive oligodendrocytes, GFP-
positive processes are shorter in KI mouse brains.
Length is reported in a.u. The scale bar represents
5 mm.
(C) Quantitative analysis of processes of GFP-
positive oligodendrocytes in WT and KI mouse
brain cortex. Data are mean ± SEM.
***p < 0.001 (three mice per group).HD (Li et al., 2001; Wang et al., 2008; Bankston et al., 2013).
Oligodendrocytes produce myelin, which electrically insulates
axons, allowing rapid and efficient propagation of nerve signals.
Defective oligodendrocyte function and deficient myelination are
found in numerous neurodegenerative diseases (Bankston et al.,
2013). In HD knockin (KI) mice that do not show obvious neuronal
loss, axonal degeneration is an early pathologic event (Li et al.,
2001). In transgenic HD monkey brain, axonal degeneration is
also seen in the absence of cell body degeneration (Wang
et al., 2008). Such axonal degeneration could be caused by
mutant Htt in axons, as well as defective oligodendrocyte func-
tion. Investigating the effect of mutant Htt in oligodendrocytes
will help us both understand the mechanism behind early dis-
ease pathology and develop more effective treatments.
We have established a transgenic mouse model that selec-
tively expresses mutant Htt in oligodendrocytes. The PLP-
150Q mice show obvious axonal degeneration and an early-
onset polyQ disease phenotype that includes impaired rotarodNeuron 85, 1212–1226performance, body weight loss, and early
death, providing strong evidence that
mutant Htt in oligodendrocytes contrib-
utes to neuronal toxicity. Furthermore,
we found that mutant Htt affects a
newly identified transcription factor,
MYRF or MRF, to reduce myelin gene
expression in mature oligodendrocytes,
offering new mechanistic insight into the
neural dysfunction and axonal degenera-
tion seen in HD.
RESULTS
Expression of Mutant Htt in
Oligodendrocytes in HD KI Mouse
Although Htt is ubiquitously expressed in
neuronal and non-neuronal cells, strong
evidence for the presence of mutant Htt
in oligodendrocytes is still lacking. Toexamine whether mutant Htt is expressed in oligodendrocytes
at the endogenous level, we crossed HD 140CAG knockin (KI)
mice with transgenic mice that selectively express GFP in oligo-
dendrocytes under the control of the proteolipid protein (PLP)
gene promoter (Mallon et al., 2002), which drives transgene
expression predominantly in oligodendrocytes in adult mouse
brain (Michalski et al., 2011). The crossed mice would thus allow
us to define whether full-length mutant Htt is expressed in GFP-
positive oligodendrocytes. Immunofluorescent staining of the
crossed mouse brains showed that GFP-positive oligodendro-
cytes (arrows in Figure 1A) do express mutant Htt, although their
Htt staining is weaker than the neuronal staining of mutant Htt.
Transgenic GFP expression in oligodendrocytes also allowed
us to clearly visualize their processes. By comparing the GFP-
positive processes in the cortex and striatum in wild-type (WT)
and KI mice, we also saw the density of these processes
reduced in the KI mouse brain (Figures 1B and S1A), as well as
short process length (Figure 1C). Because these GFP-positive, March 18, 2015 ª2015 Elsevier Inc. 1213
processes represent myelinated axons and oligodendrocyte
processes (Mallon et al., 2002), these results suggest thatmutant
Htt may affect the ability of oligodendrocytes tomyelinate axons.
Generation of PLP-150Q Transgenic Mice that
Selectively Express Mutant Htt in Oligodendrocytes
To determine whether mutant Htt in oligodendrocytes affects
their function and contributes to HD neuropathology, we set
out to establish transgenic mice that express mutant Htt under
the control of the PLP promoter. We expressed N-terminal
mutant Htt (the first 212 amino acids), including 150 glutamines
in the repeat region (Htt-150Q), based on the facts that proteol-
ysis of mutant Htt is crucial for HD pathogenesis and that N-ter-
minal mutant Htt ismisfolded and causesmore severe pathology
in animal models (Ehrnhoefer et al., 2011; Ross and Tabrizi,
2011; Lee et al., 2013). For the control, we also expressed the
same N-terminal Htt with 23Q (Htt-23Q) in transgenic mice (Fig-
ure 2A). We obtained 9 positive Htt-150Q founders and 7 positive
Htt-23Q founders. Western blot analysis with mEM48 showed
that Htt-150Q forms aggregated Htt in the stacking gel, though
its soluble level is lower than Htt-23Q in the brains of transgenic
mice (Figure 2B). Using 1C2 antibody that reacts selectively
with expanded polyQ repeats, we found that PLP-150Q is
more abundant in the brain stem, striatum, and corpus callosum,
which contain more oligodendrocytes than the cortex and cere-
bellum, in three lines of transgenic Htt-150Q mice (150Q-1,
150Q-4a, and 150Q-5). Consistent with the selective expression
revealed in oligodendrocytes by the PLP promoter, there was no
Htt-150Q detected in the peripheral tissues, including heart, kid-
ney, and muscle (Figure 2C). Immunohistochemical analysis of
the brains of 150Q-4a mice at 1, 2, and 3 months of age showed
that mutant Htt is accumulated in the corpus callosum and
striatum in an age-dependent manner (Figure 2D). Because
of the similar expression levels of transgenic Htt in different
mouse lines, we focused on the 150Q-4a (simply named PLP-
150Q) and 23Q-4 (named PLP-23Q) lines for more detailed
characterization.
Immunohistochemical studies showed that mutant Htt is
restricted in areas that are enriched in oligodendrocytes, such
as the corpus callosum, and appears to be localized in the nuclei
(Figures S1B and S1C). Compared with HD140Q KI mice, in
which mutant Htt is ubiquitously expressed in neuronal and glial
cells, PLP-150Q mice showed the selective distribution of
mutant Htt in glial cells and less abundant aggregates (Fig-
ure S1D). Using primers specific for human Htt, we performed
qRT-PCR to compare the mRNA expression levels of transgenic
Htt. Compared with mutant Htt in HD140Q KI mice at the endog-
enous level, transgenic Htt mRNA was slightly higher (Fig-
ure S2A). However, western blotting revealed that transgenic
mutant Htt in the striatum and brain stem is expressed at a lower
protein level than mutant Htt in HD140Q KI mouse brain
(Figure S2B).
To verify that transgenic mutant Htt is indeed localized in the
nuclei of oligodendrocytes, we crossed PLP-150Q mice with
PLP-GFP mice. As expected, transgenic mutant Htt is abun-
dantly distributed in the white matter region (corpus callosum)
between the cortex and striatum and is localized in the nuclei
of GFP-positive oligodendrocytes (Figure 3A). Using anti-olig21214 Neuron 85, 1212–1226, March 18, 2015 ª2015 Elsevier Inc.and anti-Htt antibodies for immunofluorescent double labeling,
we confirmed that mutant Htt accumulates and forms aggre-
gates in the nuclei of oligodendrocytes in adult PLP-150Qmouse
brain (Figure 3B). Importantly, none of these aggregate-contain-
ing cells could be labeled by antibodies to the astrocyte-specific
protein, GFAP, or the neuronal protein, NeuN (Figure 3C). These
results taken together show that we have established trans-
genic mice that express transgenic Htt specifically in mature
oligodendrocytes.
ProgressiveNeurological Phenotypes of PLP-150QMice
Transgenic mice (PLP-23Q and PLP-150Q) generated from F1
were born normally. They can be bred normally as WT mice
and do not show obvious behavioral abnormalities and motor
deficits during postnatal developmental stage and before
2months of age. However, PLP-150Qmice develop age-depen-
dent neurological symptoms starting at 3 months. We found that
old PLP-150Qmice at age of 5months display a clasping pheno-
type and reduced body weight compared with PLP-23Q mice
(Figure 4A). PLP-150Q mice at 5 months of age also have
tremors and difficulty walking (Movie S1). The body weight of
PLP-150Q mice began to decrease at the age of 4 months and
continued to decrease progressively (Figure 4B). As a result,
PLP-150Q mice started to die at 5 months of age and could
not live longer than 10 months (Figure 4C). Consistent with their
severe body weight loss and early death, PLP-150Q mice
showed a significant deficit in their motor function as measured
by rotarod performance, and this motor dysfunction became
progressively worse with age (Figure 4D). We also compared
different PLP-150Q mouse lines at a young age (2 months) and
found that all of thesemouse lines had poor rotarod performance
(Figure 4E). The locomotor activity of PLP-150Q mice is also
lower than PLP-23Q and WT mice during their active times
zone (7 p.m. to 11 p.m.) (Figure 4F). Because mutant Htt is ex-
pressed in oligodendrocytes, it may cause dysfunction of these
cells and affect axonal conductivity, which may alter the suscep-
tibility to seizure insults; thus, we next measured the latency
of mice to generalized seizure induced by flurothyl and found
that PLP-150Q mice were more sensitive to seizure induction
(Figure 4G).
Axonal Degeneration and Reduced Myelin Gene
Expression in PLP-150Q Mouse Brain
Next, we wanted to examine whether mutant Htt in PLP-150Q
mice causes any myelination defect or axonal degeneration.
The PLP-150Q/PLP-GFP crossed mice allowed us to examine
the integrity of oligodendrocyte processes. We found that there
is indeed reduced oligodendrocyte process length and no differ-
ence in the number of oligodendrocytes, in PLP-150Qmice (Fig-
ure 5A). Electron microscopy revealed that myelinated axons in
the striatum of PLP-150Q and PLP-23Q mice at the age of 1
and 2 months are not distinguishable. However, at 3 months,
there was a reduction of myelination in axons in PLP-150Q
mice compared with PLP-23Q mice, and this reduction became
more severe at 5 months (Figure 5B). Quantitative analysis of g
ratios (the inner axonal diameter to the total outer diameter)
confirmed that mutant Htt significantly increased this ratio in
PLP-150Q mice in an age-dependent manner (Figure 5C). It is
Figure 2. Generation of PLP-HD Transgenic Mice
(A) DNA construct of the vector used to generate transgenic mice expressing N-terminal Htt (1–212 amino acids) with 23Q or 150Q under the control of the PLP
promoter.
(B) EM48 western blot analysis of transgenic mouse brain regions (brain stem and striatum) expressing transgenic mutant Htt (150Q4a line) and normal Htt (23Q-2
and 23Q-4). Aggregated Htt in the stacking gel is indicated.
(C) 1C2 western blot analysis of multiple PLP-150Q lines showing mutant Htt expression in different brain tissues, but not in peripheral tissues.
(D) mEM48 immunohistochemical staining of the striatum of PLP-150Qmice at 1, 2, and 3months of age showing an increased accumulation of mutant Htt in the
older mice. Right: High-magnification micrographs. The scale bars represent 10 mm.
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Figure 3. Selective Expression of Mutant Htt in Oligodendrocytes in Adult PLP-150Q Mice
(A) PLP-150Q mice were crossed with PLP-GFP mice, resulting in PLP-150Q/GFP mice in which GFP-positive oligodendrocytes (arrows) express mutant Htt.
Immunostaining with mEM48 (red) showing that mutant Htt is enriched in the GFP-positive cells in the white matter (corpus callosum) and also localized in the
nucleus. The scale bar represents 40 mm.
(legend continued on next page)
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well known that demyelination can lead to axonal degenera-
tion (Rodriguez and Scheithauer, 1994; Sathornsumetee et al.,
2000; Lee et al., 2014). Consistently, electron microscopy also
revealed a number of degenerated axons, which appear swollen
and dark, in PLP-150Q mice at 5 months of age (Figure 5D). The
obvious axonal degeneration was not seen in 3-month-old PLP-
150Q mice, suggesting that this degeneration occurs after
demyelination (Figure S2C). We also obtained HD patient brains
that contain 45 to 53 CAG repeats in the HD gene (Table S1).
Although the ultrastructure of postmortem brain tissue was not
well preserved, we were able to identify demyelinated axons in
the HD patient brain compared with the control individual that
did not die of neurodegenerative diseases (Figure S2D).
Mutant Htt Reduces the Expression of Myelin Proteins
Tounderstand howmutantHtt affectsmyelination,weperformed
microarrays aiming to identify molecules likely to be involved in
Htt-mediated toxicity. Microarray analysis of gene expression
in PLP-150Qmouse spinal cord at 3 months revealed 998 signif-
icantly upregulated and 152 significantly downregulated genes
in PLP-150Q compared with WT mice (Figures S3A and S3B).
Of these potentially altered genes, many are important for lipid
metabolism, cell death, and proliferation (Figure S3C); their
altered expression could be secondary responses to demyelin-
ation and axonal degeneration.Myelin synthesis requires choles-
terol (Saher et al., 2011), and lipid metabolism is mediated by the
transcription factor PGC1a (Camacho et al., 2013). Previous
studies showed that the expression of PGC1a and the homeosta-
sis of cholesterol are affected in HD mouse models (Xiang et al.,
2011; Valenza and Cattaneo, 2011). qRT-PCR analysis of PGC1
a, cholesterol transport (StarD4), and sterol regulatory element
binding transcription factor 2 (SREBF2) revealed no significant
differences in their expression in the striatum of PLP-23Q and
PLP-150Q mice (Figure S3D). Further, using GFP-positive oligo-
dendrocytes that were isolated via fluorescence-activated cell
sorting from double transgenic mice expressing GFP and trans-
genic Htt in oligodendrocytes, we did not see significant differ-
ences in the expression levels of PGC1a, StarD4, and SREBF2
between WT, PLP-23Q, and PLP-150Q mice (Figures S4A and
S4B). It has been reported that MCT1, the monocarboxylate
transporter 1 that is responsible for releasing lactate and ketone
bodies from oligodendrocytes, is affected in ALS (Lee et al.,
2012).Weperformedboth qRT-PCRandwestern blotting assays
but could not see a significant defect in its expression in PLP-
150Q mouse brains (Figures S4C and S4D). Taken together,
these results suggest that when mutant Htt is selectively ex-
pressed in oligodendrocytes, it may affect the expression of
selective genes via different mechanisms.
Because there is a marked defect in myelination in PLP-150Q
mice, we performed western blotting to detect the expression
ofmyelin proteins, such as the oligodendrocyte-specific proteins
20, 30 cyclic nucleotide 30-phosphodiesterase (CNP),myelin basic
protein (MBP), myelin-associated oligodendrocytic basic protein(B) Double immunocytochemical staining with antibodies to Htt (mEM48) and Olig
striatum of 3-month-old PLP-150Q mouse. The scale bar represents 10 mm.
(C) Double staining with antibodies to GFAP and NeuN revealed that mutant H
astrocytes or NeuN-positive neuronal cells. The scale bar represents 10 mm.(MOBP) and myelin oligodendrocyte glycoprotein (MOG), in the
mouse brain and found that their expression is upregulated
from postnatal day 14 (Figure 6A). Importantly, mutant Htt does
not affect the postnatal expression ofmyelin proteins at postnatal
day 14.However, at 1month, PLP-150Qmice showeddecreases
in the expression of these oligodendrocyte-specific proteins,
in both the striatum and brain stem (Figures 6B, 6C, S5A, and
S5B). Importantly, these decreases are age dependent and
became more significant when PLP-150Q mice were 6 months
old and were also seen in different PLP-150Q mouse lines (Fig-
ures 6 and S5C). To further verify that the reduced expression
of MBP is due to the effect of nuclear mutant Htt on gene tran-
scription, we performed qPCR. Results confirmed the reduction
in MBP mRNA in PLP-150Q mouse brains (Figure 6D). To test if
reduced MBP also occurs in the brains of HD patients, we per-
formed both qRT-PCR (Figure 6E) and western blot analyses
(Figures 6F and 6G). The results indicate that MBP is indeed
decreased at both mRNA and protein levels in HD patient brains.
Because there were no significant decreases in these proteins
in the PLP-150Q mouse brains at 1 month, mutant Htt may not
have an impact on these proteins during development but may
affect mature oligodendrocytes in adult mouse brains. In support
of this idea, oligodendrocyte transcription factor (OLIG2), which
is also expressed in undifferentiated oligodendrocytes and their
precursors (Ligon et al., 2006; Meijer et al., 2012), is not affected
significantly bymutant Htt. To further verify the selective effect of
mutant Htt in adult mouse brains, we examined the expression of
neuronal and glial marker proteins in postnatal mouse brains.
Western blot results revealed no alteration of these proteins in
PLP-150Q mouse brains at P1, P7, and P14 (Figure S6A). Both
western blot and immunocytochemical analyses did not detect
either caspase-3 activation or increased GFAP (Figures S6A
and S6B). Immunocytochemical analyses of NeuN and olig2
staining also support the western blot results, which demon-
strate the unaltered expression of these neuronal and oligoden-
drocyte-specific proteins in PLP-150Q mouse brains (Fig-
ure S6C). By counting the number of Olig2-positive cells (WT:
268.000 ± 4.626; 23Q: 262.333 ± 8.939; 150Q: 272.333 ±
6.726; n = 3 mice/group) and NeuN (WT: 1263.333 ± 45.507;
23Q: 1292.667 ± 65.787; 150Q: 1201.333 ± 27.591; n = 3
mice/group), we did not find any difference between WT, PLP-
23Q, and PLP-150Q mice at P14. In addition, we did not find
that mutant Htt affects proliferation of glial cells in the corpus cal-
losum of PLP-150Q mice and differentiation of cultured oligo-
dendrocytes from PLP-150Q mice (Figure S7). All these results
support the idea that mutant Htt affects the expression of myelin
genes in an age-dependent manner, which is consistent with the
aging-related and progressive symptoms of HD mice.
Mutant Htt Binds N-Terminal MYRF and Affects Its
Transcription Activity
The decrease in several oligodendrocyte-specific proteins led us
to focus on the transcription factors that mediate the expression2 showing the selective expression of mutant Htt in oligodendrocytes in in the
tt is expressed in GFP-positive oligodendrocytes, but not in GFAP-positive
Neuron 85, 1212–1226, March 18, 2015 ª2015 Elsevier Inc. 1217
Figure 4. Progressive Neurological Symptoms of PLP-150Q Mice
(A) Representative photos of PLP-23Q and PLP-150Q mice, 6 months old. Data are mean ± SEM.
(B) Age-dependent loss of body weight in PLP-150Q mice; at least 15 animals per group. Two-way ANOVA, p < 0.05. *Significant compared with PLP-23Q;
**significant compared with PLP-23Q and WT.
(C) Early death of PLP-150Q mice. The survival plot shows that PLP-150Q mice die at the age of 5 to 10 months (n = 15).
(D) Age-dependent worsening of rotarod performance of PLP-150Qmice compared withWT and PLP-23Q control mouse lines. At least 15 animals per genotype
were examined. Data are mean ± SEM.
(E) Motor deficits in different PLP-150Q mouse lines compared with the PLP-23Q mouse line (n = 5). Data are mean ± SEM. One-way ANOVA, p < 0.05.
(F) Locomotor activity was recorded for 24 hr. Statistical analysis shows reduced activity of PLP-150Qmice during the dark cycle (n = 8 or 9, 2–3 months of age).
Data are mean ± SEM. Two-way ANOVA, p < 0.05.
(G) Increased susceptibility of PLP-150Q mice to flurothyl-induced seizures. At least 10 animals per genotype, 3 to 6 months of age. Data are mean ± SEM.
One-way ANOVA, p < 0.05.of these proteins. Recently, myelin regulatory factor (MYRF) was
found to regulate the expression of myelin-specific proteins (Em-
ery et al., 2009; Hornig et al., 2013). MYRF is not expressed in
oligodendrocyte precursors (OPCs) (McKenzie et al., 2014) but
expressed only in postmitotic oligodendrocytes (Cahoy et al.,
2008), and its depletion in oligodendrocytes causes failures in1218 Neuron 85, 1212–1226, March 18, 2015 ª2015 Elsevier Inc.myelin gene expression and myelin formation (Emery, 2010).
However, western blotting showed that MYRF is not decreased
in the brains of PLP-150Q mice (Figure 6B). Because mutant
N-terminal Htt is able to interact with a number of transcription
factors in neuronal cells (Harjes and Wanker, 2003; Li and Li,
2004), we wanted to know whether mutant Htt interacts with
Figure 5. Demyelination and Axonal Degen-
eration in PLP-150Q Mice
(A) Loss of oligodendrocyte processes in the brain
cortex in PLP-150Q mouse. Quantitative analysis
of the number of GFP-positive oligodendrocytes
and process length is shown on the right. Oligo-
dendrocytes in PLP-150Q mouse brain have
significantly shorter processes than PLP-23Q.
Process length is reported in a.u. Data are mean ±
SEM. **p < 0.01.
(B) Electron microscopic graphs of the striatum
of PLP-23Q and PLP-150Q mice at 1, 2, 3, and
5 months of age. When PLP-150Q mice become
old (3 and 5 months), they show demyelination
compared with 1-month-old PLP-150Q mice and
the age-matched PLP-23Q mice. The scale bars
represent 0.5 mm.
(C) G ratios were calculated and plotted against
axon diameter with linear regression. G ratios
were significantly increased in PLP-150Q striatum
(g = 0.7568 ± 0.0068) comparedwith age-matched
WT and PLP-23Q (g = 0.6315 ± 0.0099 and g =
0.6083 ± 0.0095, respectively). One-way ANOVA,
p < 0.05. At least 327 axons per genotype were
examined.
(D) Axonal degeneration and demyelination
were also seen in PLP-150Q mice at the age of
5 months. The scale bar represents 0.5 mm.MYRF and affects myelin gene expression. To that end, we first
generated the plasmid encoding mouse MYRF and expressed it
in transfected HEK293 cells. We found that MYRF is unstable
and cleaved to a smaller N-terminal fragment, which is labeled
by an antibody against the N-terminal region of MYRF (Fig-
ure 7A). This finding is consistent with the recent report that
MYRF can be self-cleaved (Bujalka et al., 2013; Li et al., 2013).
Treatment of cells with the proteasome inhibitor MG132 signifi-
cantly increased the expression levels of full-length MYRF and
its cleaved products (Figure 7B). Using brain tissues of HD KI
mice that express full-length mutant Htt at the endogenous level,
we performed Htt immunoprecipitation and found that more
N-terminal MYRF (nMYRF) was also co-precipitated with mutant
Htt (Figure 7C). To verify that this in vivo interaction also occurs in
our transgenic Htt mouse brain tissues, we performed Htt immu-Neuron 85, 1212–1226noprecipitation and found that mutant Htt
could co-precipitate more nMYRF than
full-length MYRF (Figure 7D).
Although the above immunoprecipita-
tions demonstrate the in vivo interaction
of MYRF with mutant Htt, it remains un-
clear whether mutant Htt binds more
nMYRF than normal Htt as the antibodies
(mEM48 and 1C2) we used for immuno-
precipitation and western blotting pref-
erentially reacts with mutant Htt and
precipitatesmoremutant Htt. To examine
whether mutant Htt binds abnormally to
MYRF, we used transfected cells to ex-
press N-terminal Htt andMYRF for study-ing their interactions. We generated nMYRF tagged with theMyc
epitope and C-terminal MYRF (cMYRF) tagged with the FLAG
epitope (Figure 7E). Transfection of these two proteins in
HEK293 cells confirmed that nMYRF is localized in the nucleus,
and cMYRF is in the cytoplasm (Figure 7F). These results are in
agreement with recent findings that nMYRF, once generated
from the self-cleavage of full-length MYRF, is able to translocate
into the nucleus to execute its transcription function (Bujalka
et al., 2013; Li et al., 2013).
By co-expressing nMYRF or cMYRF with NLS-tagged
N-terminal Htt (1-212 amino acids) containing 23Q or 150Q in
HEK293 cells and performing immunoprecipitation of trans-
fected MYRF, we found that more Htt-150Q was precipitated
by nMYRF when the same levels of Htt-23Q and Htt-
150Q were present in the input (Figure 8A). In contrast,, March 18, 2015 ª2015 Elsevier Inc. 1219
Figure 6. Reduced Expression of Myelin Genes in PLP-150Q Mice
(A) Western blotting showing upregulation of multiple myelin proteins (MBP, CNP, MOBP, and MOG) in the mouse brains during postnatal days, which is not
affected by mutant Htt.
(B) Western blotting showing the age-dependent decrease of myelin proteins (MBP, CNP, MOBP, and MOG) in the brain stem of adult PLP-150Q, but not PLP-
23Q and WT, mice. Transcription factor MYRF for the myelin genes and oligodendroglial lineage marker olig-2 remain unchanged in PLP-150Q mouse brain.
(C) Densitometric analysis of the relative levels of myelin proteins (ratio of myelin protein to GAPDH) in (B). Data are mean ± SEM.
(D) qPCR of MBP transcripts verified that MBP mRNA levels are reduced in PLP-150Q mouse brain (n = 3/genotype). Data are mean ± SEM.
(A–D) n = 3 per genotype and age. Data are mean ± SEM. Two-way ANOVA, p < 0.05.
(E and F) qPCR (E) and western blot (F) analysis of the expression of MBP in the brain cortex of HD patients and control individuals (n = 3 each group). Data are
mean ± SEM.
(G) The relative levels of MBP were quantified by measuring the ratios of MBP to GAPDH on the western blots in (F). Data are mean ± SEM. *p < 0.05; **p < 0.01.immunoprecipitation of cMYRF failed to precipitate transfected
Htt (Figure 8B). These results support the in vivo interaction of
mutant Htt with nMYRF in HD mouse brains (Figures 7C and
7D). To further verify that mutant Htt can interact with MYRF
directly, we performed an in vitro binding assay using in vitro syn-
thesized Htt incubated with GST-nMYRF fusion proteins. The1220 Neuron 85, 1212–1226, March 18, 2015 ª2015 Elsevier Inc.result also showed that more mutant Htt bound to GST-nMYRF
than normal Htt (Figure 8C). By expressing different fragments of
MYRF with mutant Htt in transfected cells and co-immunopre-
cipitation, we found that nMYRF containing the proline-rich
domain interacts with Htt and that polyQ expansion could
increase this interaction (Figure S8A-D). Because nMYRF has
Figure 7. Interaction of Mutant Htt with
MYRF
(A) Comparison of in vitro synthesized and trans-
fected MYRF showing that transfected full-length
MYRF is cleaved to nMYRF in cells.
(B) Inhibition of MG132 markedly increased the
levels of transfected full-length MYRF and nMYRF,
suggesting that the ubiquitin-proteasome system
degrades them.
(C) Immunoprecipitation of mutant Htt from HD KI
mouse brain selectively co-precipitates nMYRF.
WT and IgG IP served as controls.
(D) Immunoprecipitation of mutant Htt via mEM48
from PLP-150Q transgenic mouse brain also
selectively co-precipitates nMYRF. Htt-150Q was
preferentially labeled by 1C2 antibody on western
blot (left). More nMYRF than full-length MYRF
was precipitated with mutant Htt (right top). Anti-
GAPDH was also used to probe the immunopre-
cipitates (right bottom).
(E) Expression of MYRF, nMYRF (1–635 aa), and
cMYRF (616–1,151 aa) in HEK293 cells. MYRF and
nMYRF were detected with anti-myc, whereas
cMYRF was detected by anti-FLAG.
(F) Transfection of nMYRF and cMYRF into
HEK293 cells revealed that only nMYRF is local-
ized in the nucleus, supporting its role in gene
transcription. The scale bars represent 20 mm.transcriptional activity, the binding of mutant Htt to the N-termi-
nal region of MYRF also supports the idea that this interaction
affects the transcription activity of MYRF. Also, the interaction
between mutant Htt and MYRF suggests that soluble mutant
Htt binds MYRF, which is supported by immunofluorescent
staining of transfected cells in which soluble MYRF is diffuse
with mutant Htt in the nucleus, but is not colocalized with Htt
aggregates (Figure S8E).
On the basis of the above findings, we went on to test whether
mutant Htt affects the transcription activity of MYRF. For this
assay, we isolated the promoter region of the mouse MBP
gene on the basis of an earlier finding (Mack et al., 2007) and
linked this promoter with the luciferase reporter. An assay of
luciferase reporter activity showed that MYRF significantly
increased the MBP promoter activity, which was inhibited by
mutant Htt (Figure 8D). Importantly, nMYRF, but not cMYRF,
could also stimulate the MBP promoter activity and reverse theNeuron 85, 1212–1226inhibition caused by mutant Htt (Fig-
ure 8E). Via chromatin immunoprecipita-
tion (ChIP) assay, we immunoprecipitated
nMYRF associated-DNAs in the presence
of normal and mutant Htt and measured
the associated MBP promoter DNAs
using qPCR. We found that mutant Htt
significantly inhibited the association of
nMYRF with the MBP promoter (Fig-
ure 8F). These results support the idea
that mutant Htt binds nMYRF to affect
its transcription activity by altering its as-
sociation with DNAs. On the basis of thefact that MYRF is self-cleaved to nMYRF, which is then translo-
cated into the nucleus to activate myelin gene expression (Bu-
jalka et al., 2013; Li et al., 2013), we propose a model in which
N-terminal mutant Htt accumulates in the nuclei of oligodendro-
cytes in an age-dependent manner. This age-related accumu-
lation causes mutant Htt to bind nMYRF in mature oligodendro-
cytes and affects its transcription activity, resulting in decreased
expression of myelin genes and an associated myelination defi-
ciency and axonal degeneration in HD (Figure 8G).
DISCUSSION
By establishing transgenic mice that express mutant Htt selec-
tively in oligodendrocytes, we provide strong evidence for the
important contribution of mutant Htt in oligodendrocytes to
HD neuropathology. We also show that mutant Htt can affect
cell type-specific gene expression to reduce myelin gene, March 18, 2015 ª2015 Elsevier Inc. 1221
Figure 8. Mutant Htt Binds nMYRF and Inhibits Its Transcription Activity
(A) Co-transfection of nMYRF (left) with N-terminal Htt containing 23Q or 150Q into HEK293 cells and immunoprecipitation of nMYRF. More Htt-150Q binds
nMYRF than Htt-23Q. Co-transfection of cMYRF (right) with N-terminal Htt containing 23Q or 150Q into HEK293 cells showing no interaction between cMYRF
and Htt.
(B) The ratio of precipitated to input in (A) is shown. Data are mean ± SEM.
(C) GST-nMYRF and GST were expressed and purified to incubate with in vitro synthesized N-terminal Htt containing 23Q and 150Q, also demonstrating that
mutant Htt directly binds more MYRF.
(D) MBP promoter was co-expressed with MYRF and Htt to assess its transcription activity via luciferase assay. MYRF markedly promotes MBP promoter
activity. Co-expression of N-terminal Htt with 23Q did not significantly (p > 0.05) affect the MBP promoter activity, whereas Htt-150Q significantly (p < 0.001)
reduces the MBP promoter activity. *p < 0.05; ***p < 0.001. Data are mean ± SEM.
(legend continued on next page)
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expression, leading to axonal degeneration. In addition, we find
that mutant Htt affects MYRF transcription activity via its
abnormal association with MYRF, providing mechanistic insight
into the specific effect of mutant Htt on a particular type of non-
neuronal cell.
Although transgenic mice expressing N-terminal mutant Htt
are valuable models for exploring the pathogenesis of HD,
whether their pathological characteristics can be replicated in
HDmousemodels that express full-length mutant Htt merits dis-
cussion here. All full-length Htt HD mouse models, transgenic or
KI, show milder disease progression than transgenic mice ex-
pressing N-terminal mutant Htt (Menalled and Chesselet, 2002;
Heng et al., 2008). Because only N-terminal mutant Htt is able
to misfold and form aggregates, proteolysis of full-length mutant
Htt has been widely held to be an important process toward HD
pathogenesis (Ehrnhoefer et al., 2011; Lee et al., 2013; Ross
et al., 2014). In this regard, the expression of N-terminal mutant
Htt can facilitate disease progression and yield robust pheno-
types in mice, allowing us to identify pathogenic pathways and
evaluate therapeutic targets (Menalled and Chesselet, 2002;
Heng et al., 2008). One good example is that young R6/2 mice
at 3 to 4 months of age, which express exon1 mutant Htt, reca-
pitulate many pathological changes seen in the end stage of HD
KI mice at 2 years of age (Woodman et al., 2007).
Mutant Htt affects the function of neuronal and glial cells in the
brain. Because HD pathogenesis involves cell-autonomous and
non-cell-autonomous toxicity of mutant Htt (Gu et al., 2005),
generating animal models with cell type-specific expression of
mutant Htt is important to dissect HD pathogenesis. In our
PLP-150Q transgenic mice, we saw that mutant Htt in oligoden-
drocytes forms aggregates in their nuclei, interacts with the
oligodendrocyte-specific transcription factor, MYRF, and re-
duces myelin gene expression. All these important pathogenic
events were also seen in HD KI mouse brains. Moreover, the ef-
fect of mutant Htt on axons in PLP-150Q mice is consistent with
our early findings that axonal degeneration is seen in the brains
of a HD KI mouse model (Li et al., 2001) and transgenic monkey
brains (Wang et al., 2008). Oligodendrocytes and myelin
abnormalities can slow or stop fast axon transport, resulting in
synaptic loss and axonal degeneration (Han et al., 2010). Our
PLP-150Qmouse model supports the idea that axonal degener-
ation can also be caused by the non-cell-autonomous toxicity of
mutant Htt in oligodendrocytes.
That said, however, PLP-150Q mice develop much more pro-
gressive and severe phenotypes, even when mutant Htt is selec-
tively expressed in oligodendrocytes. Such severe phenotypes
are unlikely to be due to the overexpression of N-terminal mutant
Htt, because the level of Htt-150Q is lower than the control trans-
genic Htt-23Q, which did not elicit any neurological phenotypes.(E) Expression of nMYRF, but not cMYRF, could rescue the inhibitory effect ofmut
mean ± SEM.
(F) qPCR quantification of the MBP promoter DNAs associated with Myc-nMYR
obtained from three independent experiments. **p = 0.019. Data are mean ± SE
(G) A proposed model for the effect of mutant Htt in oligodendrocytes. According
cleaved to nMYRF, which is dissociated from ER and translocalized to the nuc
N-terminal mutant Htt in the nucleus can lead to the abnormal binding of nMYRF
genes and oligodendrocyte dysfunction.Also, other transgenic HD mouse models expressing N-terminal
mutant Htt at levels lower than endogenous mouse Htt in either
astrocytes or axonal terminals show early death and progressive
phenotypes (Bradford et al., 2009: Xu et al., 2013). All these find-
ings suggest that once N-terminal mutant Htt accumulates in ol-
igodendrocytes, it can greatly facilitate disease progression.
Our identification of the effect mutant Htt has on MYRF-medi-
ated myelin gene expression is consistent with the findings that
N-terminal mutant Htt can interact with a number of transcription
factors and affect gene transcription (Harjes and Wanker, 2003;
Li and Li, 2004). A new insight from our study is that the transcrip-
tion dysfunction in oligodendrocytes is both cell type specific
and protein context dependent. Our findings also suggest that
mutant Htt affects the function of mature oligodendrocytes.
The accumulation of N-terminal mutant Htt in the nuclei of
mature oligodendrocytes in adult mice is age dependent, as evi-
denced by the following facts: (1) PLP-150Q mice show
increased accumulation of mutant Htt in the adult brain with ag-
ing, (2) PLP-150Q mice display demyelination and reduced
myelin gene expression in an age-dependent manner, and (3)
PLP-150Qmice develop age-dependent and progressive neuro-
logical symptoms. Perhaps in mature oligodendrocytes, mutant
Htt is prone to accumulating in their nuclei, thereby affecting
gene expression. Consistent with these facts, we also found
that mutant Htt did not affect the survival of neuronal cells and
oligodendrocyte proliferation during early postnatal develop-
ment. Although the PLP promoter was found to drive gene
expression in different types of cells during embryonic and early
developmental stages, transgenic gene expression under this
promoter becomes restricted to oligodendrocytes in adult
mouse brain (Michalski et al., 2011). Mutant Htt-mediated
toxicity in oligodendrocytes requires an age-dependent accu-
mulation of misfolded Htt in cells. It is likely that mature oligoden-
drocytes are less capable of clearing misfolded N-terminal Htt
than undifferentiated precursor cells. Thus, the expression of
N-terminal mutant Htt, which is prone to misfolding, even at a
low level, could greatly facilitate the accumulation of the toxic
form of mutant Htt in oligodendrocytes, whereas in HD KI
mice, it takes a much longer time to accumulate N-terminal
mutant Htt after being generated by the proteolysis of full-length
mutant Htt.
The idea that mutant Htt affects the expression of selective
genes in mature oligodendrocytes is also supported by the fact
that mutant Htt does not reduce the expression of OLIG2, which
is expressed predominantly in OPC cells and undifferentiated ol-
igodendrocytes. Because OLIG2 is also present in mature oligo-
dendrocytes andMYRF is restricted to mature oligodendrocytes
(Cahoy et al., 2008; Emery et al., 2009), the negative impact of
mutant Htt on OLIG2 is consistent with the finding that OLIG2ant Htt on theMBP promoter activity. *p < 0.05; **p < 0.01; ***p < 0.001. Data are
F that was immunoprecipitated by anti-Myc in ChIP assay. The results were
M.
to recent studies (Bujalka et al., 2013; Li et al., 2013), full-length MYRF is self-
leus to activate the expression of myelin genes. In HD, the accumulation of
and affects its transcription activity, leading to reduced expression of myelin
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expression is not mediated by MYRF (Emery et al., 2009) and in-
dicates a specific effect of mutant Htt on MYRF. Another line of
evidence to support the specific effect of mutant Htt in oligoden-
drocytes is the negative impact of mutant Htt on the expression
of MCT1. MCT1 transports lactate from oligodendrocytes to
support neuronal survival and was found to be reduced in oligo-
dendrocytes in ALS mouse brains (Lee et al., 2012). Because
mutant SOD1 in ALS is expressed largely in the cytoplasm, the
cytoplasmic effect of mutant SOD1 may reduce the expression
of MCT1, which is different from the nuclear effect of mutant
Htt, via a different mechanism.
Because oligodendrocytes are critical for axonal function and
are also a desirable transplant population for remyelination stra-
tegies, the findings from our study provide a new therapeutic
target for treating HD. Oligodendrocytes are generated mostly
during the postnatal periods (P7–P14) in rodents. These cells
differentiate from proliferative, migratory OPCs and produce
myelin proteins required for myelination. Althoughmost myelina-
tion occurs early in life, myelination processes may exhibit sub-
stantial plasticity in adult brains and have evolved to combat a
range of infectious, metabolic, and immune insults, which can
cause demyelination and lead to multiple sclerosis (Paus et al.,
1999; Franklin and Ffrench-Constant, 2008; Emery, 2010). A
recent study demonstrates that depletion of MYRF prevents
adult myelination, reduces the production of new oligodendro-
cytes during adulthood, and affects motor skill learning in mice
(McKenzie et al., 2014). Newly differentiated oligodendrocytes
are widely thought to generate additional myelin (Franklin and
Ffrench-Constant, 2008; Emery, 2010), and on the basis of this
idea, approaches to promote differentiation of OPCs into myeli-
nating oligodendrocytes have been hotly pursued for the treat-
ment of demyelination-related pathology (Rivers et al., 2008;
Boulanger and Messier, 2014). Our studies indicate that mutant
Htt affects mature oligodendrocytes to cause a decrease in
myelin proteins and subsequent loss of myelin, suggesting that
the production of myelin proteins in mature oligodendrocytes is
important for the maintenance of myelin in adult brains as well
(Koenning et al., 2012). This idea is also supported by the finding
that mutant Htt does not reduce Olig2 but rather affects the func-
tion of MYRF, which is expressed only in postmitotic oligoden-
drocytes (Cahoy et al., 2008; Emery et al., 2009; McKenzie
et al., 2014). The findings of our study therefore suggest that
improving the function of mature oligodendrocytes should at
least be beneficial in HD and perhaps other age-dependent
neurodegenerative diseases that involve the dysfunction of
mature oligodendrocytes and associated axonal dysfunction
as well.EXPERIMENTAL PROCEDURES
Animals
To generate PLP-Htt transgenic mice, cDNA encoding N-terminal human
Htt (amino acids 1–212) containing 23Q or 150Q was subcloned into the
pNEB193 vector using BamHI and XbaI. The plasmid was then digested with
PmeI and AscI, and the Htt-containing fragment was inserted into the PLP pro-
moter cassette. The pNEB193 vector and PLP promoter cassette were gener-
ated previously (Fuss et al., 2000). Pronuclear injection of the linearized
construct was performed by the Transgenic Mouse and Gene Targeting Core
at Emory University. Founder mice were obtained andmaintained at the Emory1224 Neuron 85, 1212–1226, March 18, 2015 ª2015 Elsevier Inc.mouse facility.GenomicDNAwas isolated frommouse tails, andPCRgenotyp-
ing with primers that flank the polyQ region was used to screen for transgenic
mice. The sequences of the primers are as follows: forward, 50-ATGAAG
GCCTTCGAGTCCCTCAAGTCCTTC-30, and reverse, 50-AAACTCACGGTCGG
TGCAGCGGCTCCTCAG-30. We identified nine positive PLP-150Q founders
and seven positive PLP-23Q founders. Transgene expression was determined
via western blotting. PLP-GFP mice were obtained from Dr. Wendy Macklin
(University of Colorado Denver) and bred with PLP-Htt mice to generate
double-transgenic mice. Full-length mutant Htt CAG140Q (HD KI) mice were
provided by Dr. Michael Levine (University of California, Los Angeles). All
mice were bred and maintained in the animal facility at Emory University under
specific pathogen-free conditions in accordance with the institutional guide-
lines of the Animal Care and Use Committee at Emory University.
Mouse Behavior Analysis
Mouse body weight was measured once every month, and survival was moni-
tored regularly. The motor function of the mice was assessed with the rotarod
test (Rotamex; Columbus Instruments). Mice were trained on the rotarod at
5 rpm for 5 min for 3 consecutive days. After training, the mice were tested
for 3 consecutive days, three trials per day. The rotarod gradually accelerated
to 40 rpm over a 5 min period. Latency to fall was recorded for each trial. At
least 15 mice were analyzed per group when comparing PLP-150Q, PLP-
23Q, and WT. When comparing all PLP-150Q lines, at least 5 animals were
analyzed per group.
The flurothyl-induced seizure experiment was performed as previously
described (Makinson et al., 2014). Mice were placed in a clear Plexiglas cham-
ber and exposed to flurothyl (2,2,2-trifluroethylether) (Sigma, 287571) at a rate
of 20 ml/min. Latency to generalized seizure was recorded. Mice were at least
3 months old, and at least ten animals were analyzed for each group. Locomo-
tor activity was assessed using an automated system (PAS; San Diego Instru-
ments) that records all photobeam interruptions. Each mouse was housed in a
separate chamber with food and water. Activity was recorded once every
30 min for 30 hr. The first 6 hr were excluded from analysis. At least eight
animals were analyzed per group.
Immunofluorescence, Immunohistochemistry, and Electron
Microscopy
Mice were anaesthetized with 5% chloral hydrate and perfused with 0.9%
NaCl, followed by 4% paraformaldehyde (PFA). The brains were removed
and post-fixed in 4% PFA overnight at 4C. The brains were transferred to
30% sucrose for 48 hr, then cut to 20- or 40-mm sections with the cryostat (Le-
ica CM1850) at20C. Sections were blocked in 4% donkey serumwith 0.2%
Triton X-100 and 3% BSA in PBS for 1 hr. For immunofluorescent staining,
20 mm sections were incubated with primary antibodies in the same buffer at
4C overnight. After washing with 1X PBS, the sections were incubated in fluo-
rescent secondary antibodies andHoechst stain. Fluorescent imageswere ac-
quired with a Zeiss microscope (Carl Zeiss Imaging, Axiovert 200 MOT) and
either a 403 or 633 lens (LD-Achroplan 403/0.6 or 633/0.75) with a digital
camera (Hamamatsu, Orca-100) and Openlab software (Improvision). For
immunohistochemistry with DAB staining, after blocking, 40 mm sections
were incubated with mEM48 for at least 48 hr at 4C. A biotin/avidin immuno-
assay (Vector Laboratories) and DAB kit (Invitrogen, 00-2020) were used. Im-
ages were acquired with a Zeiss microscope (Carl Zeiss Imaging, Imager A.2)
and either a 403 or 633 lens (Plan-Apochromat 403/0.95 or 633/1.4) with a
digital camera (Carl Zeiss Imaging, AxioCam HRc) and AxioVision software.
For electro-microscope study, mice were perfused with 0.9%NaCl followed
by 4% PFA containing 2.5% glutaraldehyde. After post-fixation, the brain was
cut to 50-mm sections using the vibratome (Leica, VT1000). The sections were
processed as previously described (Wang et al., 2008). Axon and myelin fiber
diameters were measured using ImageJ (NIH). More than 300 axons were
examined for each genotype.
Statistical Analysis
Results are expressed asmean ± SEM. Prism6 (GraphPad Software) was used
for statistical analysis. When only two experimental groups were compared,
Student’s t test was used to calculate statistical significance. For all other ex-
periments, statistical significance was calculated using one-way ANOVA or
two-way ANOVA, followed by Tukey’s multiple-comparisons test. A p value <
0.05 was considered significant.
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